These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 21502575)

  • 1. Inhibitors of the platelet thrombin receptor: will they live up to their promises?
    Van de Werf F
    Circulation; 2011 May; 123(17):1833-5. PubMed ID: 21502575
    [No Abstract]   [Full Text] [Related]  

  • 2. Antithrombotic effects of the novel inhibitor of thrombin-induced offtelet aggregation and thrombus formation, 3-[2-[1,1':2',1"]-terphenyl-4'-yl)ethyl]phenoxyacetic acid.
    Miyamae T; Hashizume H; Ogawa T; Okayama T; Nukui E; Oshima K; Morikawa T; Hagiwara M
    Arzneimittelforschung; 1997 Jan; 47(1):13-8. PubMed ID: 9037437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs.
    Kogushi M; Matsuoka T; Kawata T; Kuramochi H; Kawaguchi S; Murakami K; Hiyoshi H; Suzuki S; Kawahara T; Kajiwara A; Hishinuma I
    Eur J Pharmacol; 2011 Apr; 657(1-3):131-7. PubMed ID: 21300059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombin as a common downstream target blocking both platelet and monocyte activation.
    Santilli F; Davì G
    Thromb Haemost; 2009 Feb; 101(2):220-1. PubMed ID: 19190800
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined blockade of thrombin anion binding exosite-1 and PAR4 produces synergistic antiplatelet effect in human platelets.
    Wu CC; Wang WY; Wei CK; Teng CM
    Thromb Haemost; 2011 Jan; 105(1):88-95. PubMed ID: 21057701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing the platelet.
    Futterman LG; Lemberg L
    Am J Crit Care; 1997 Sep; 6(5):406-14. PubMed ID: 9283679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment of human platelets with plasmin inhibits responses to thrombin, but potentiates responses to low concentrations of aggregating agents, including the thrombin receptor activating peptide, SFLLRN.
    Kinlough-Rathbone RL; Perry DW; Rand ML; Packham MA
    Thromb Haemost; 1997 Apr; 77(4):741-7. PubMed ID: 9134653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet drugs.
    De Meyer SF; Vanhoorelbeke K; Broos K; Salles II; Deckmyn H
    Br J Haematol; 2008 Aug; 142(4):515-28. PubMed ID: 18513285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet therapy in coronary heart disease. Emerging strategies for the treatment and prevention of acute myocardial infarction.
    Becker RC
    Arch Pathol Lab Med; 1993 Jan; 117(1):89-96. PubMed ID: 8418769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clopidogrel attenuates coated-platelet production in patients undergoing elective coronary catheterization.
    Norgard NB; Saya S; Hann CL; Hennebry TA; Schechter E; Dale GL
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):536-9. PubMed ID: 19034031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Indications for the use of platelet inhibitors].
    Kummer H; Sturm V
    Ther Umsch; 1977 May; 34(5):373-8. PubMed ID: 325681
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of platelet thromboxane receptor function by a thrombin receptor-targeted pepducin.
    Stampfuss JJ; Schrör K; Weber AA
    Nat Med; 2003 Dec; 9(12):1447; author reply 1447-8. PubMed ID: 14647510
    [No Abstract]   [Full Text] [Related]  

  • 13. Glybenclamide: an antidiabetic with in vivo antithrombotic activity.
    Ting HJ; Khasawneh FT
    Eur J Pharmacol; 2010 Dec; 649(1-3):249-54. PubMed ID: 20858477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Insights Into the Regulation of Coagulation and Thrombosis.
    Li X; Sim MMS; Wood JP
    Arterioscler Thromb Vasc Biol; 2020 May; 40(5):e119-e125. PubMed ID: 32320291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protease receptor antagonism to target blood platelet therapies.
    Holinstat M; Bray PF
    Clin Pharmacol Ther; 2016 Jan; 99(1):72-81. PubMed ID: 26501993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin receptor antagonists as novel therapeutic targets.
    Chackalamannil S
    Curr Opin Drug Discov Devel; 2001 Jul; 4(4):417-27. PubMed ID: 11727307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonists.
    Clasby MC; Chackalamannil S; Czarniecki M; Doller D; Eagen K; Greenlee WJ; Lin Y; Tsai H; Xia Y; Ahn HS; Agans-Fantuzzi J; Boykow G; Chintala M; Foster C; Bryant M; Lau J
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1544-8. PubMed ID: 16380251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Do all the patients with adult-onset diabetes mellitus need acetylsalicylic acid?].
    Lassila R
    Duodecim; 1999; 115(10):1174-7. PubMed ID: 11877857
    [No Abstract]   [Full Text] [Related]  

  • 19. Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3.
    Wu CC; Hwang TL; Liao CH; Kuo SC; Lee FY; Lee CY; Teng CM
    Thromb Haemost; 2002 Jun; 87(6):1026-33. PubMed ID: 12083482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys.
    Chintala M; Strony J; Yang B; Kurowski S; Li Q
    Arterioscler Thromb Vasc Biol; 2010 Nov; 30(11):2143-9. PubMed ID: 20798382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.